Analyzing LEGN Stock – A Brief Investor Report

By Ken Smith • Friday, June 06 15:14 • Permanent Link

Legend Biotech logged a 10.4% change during today's afternoon session, and is now trading at a price of $34.75 per share. The S&P 500 index moved 1.0%. LEGN's trading volume is 2,785,275 compared to the stock's average volume of 1,570,366.

Legend Biotech trades -54.53% away from its average analyst target price of $76.42 per share. The 21 analysts following the stock have set target prices ranging from $53.12 to $95.0, and on average have given Legend Biotech a rating of buy.

Anyone interested in buying LEGN should be aware of the facts below:

Legend Biotech has moved -30.9% over the last year, and the S&P 500 logged a change of 11.1%
Based on its trailing earnings per share of -1.18, Legend Biotech has a trailing 12 month Price to Earnings (P/E) ratio of -29.4 while the S&P 500 average is 29.3
LEGN has a forward P/E ratio of -51.9 based on its forward 12 month price to earnings (EPS) of $-0.67 per share
Its Price to Book (P/B) ratio is 6.28 compared to its sector average of 3.19
Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe.
Based in Somerset, the company has 2,700 full time employees and a market cap of $6.4 Billion.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.